High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 501–600 of 1,017
Generation of Transgene-Free Maize Male Sterile Lines Using the CRISPR/Cas9 System
Chen, R., Xu, Q., Liu, Y., Zhang, J., Ren, D., Wang, G., & Liu, Y. (2018) · Frontiers in Plant Science · doi:10.3389/fpls.2018.01180 · Cited by 88
A simple, flexible and high‐throughput cloning system for plant genome editing via CRISPR‐Cas system
Kim, H., Kim, S., Ryu, J., Choi, M. K., Kweon, J., Kang, B., Ahn, H., Bae, S., Kim, J., Kim, J., et al. (2016) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12474 · Cited by 88
Atkins, A., Chung, C.-H., Allen, A. G., Dampier, W., Gurrola, T. E., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. L. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.673022 · Cited by 90
“TTISS was used to examine the balance between specificity and activity in nine SpCas9 variants including wild-type SpCas9, seven previously published variants, and one novel variant (Kleinstiver et al., 2016; Slaymaker et al., 2016; Chen et al., 2017a; Casini et al., 2018; Hu et al., 2018; Lee et al., 2018; Vakulskas…”
MethodDeep learning models to predict the editing efficiencies and outcomes of diverse base editors
Kim, N., Choi, S.-C., Kim, S., Song, M., Seo, J. H., Min, S., Park, J., Cho, S., & Kim, S. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01792-x · Cited by 85
PAX6 regulates human corneal epithelium cell identity
Kitazawa, K., Hikichi, T., Nakamura, T., Sotozono, C., Kinoshita, S., & Masui, S. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.11.005 · Cited by 82
CRISPRoff enables spatio-temporal control of CRISPR editing
Carlson-Stevermer, J., Kelso, R., Kadina, A. P., Joshi, S., Rossi, N., Walker, J., Stoner, R., & Maures, T. J. (2020) · Nature Communications · doi:10.1038/s41467-020-18853-3 · Cited by 78
Wen, W., Quan, Z.-J., Li, S.-A., Yang, Z.-X., Fu, Y.-W., Zhang, F., Li, G., Zhao, M., Yin, M., Xu, J., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02462-4 · Cited by 81
Generating High-Fidelity Cochlear Organoids from Human Pluripotent Stem Cells
Moore, S. T., Nakamura, T., Nie, J., Solivais, A. J., Aristizábal-Ramírez, I., Ueda, Y., Manikandan, M., Vummidi, S. R., Romano, D. R., Hoffman, J. R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2023.06.006 · Cited by 81
James, S. L., Marshall, J. M., Christophides, G. K., Okumu, F. O., & Nolan, T. (2020) · Vector-Borne and Zoonotic Diseases · doi:10.1089/vbz.2019.2606 · Cited by 80
“They also noted that new endonuclease enzymes with increased sequence fidelity are being developed for human therapeutic applications (e.g., Kleinstiver et al. 2016), which also could be tested for development of gene drive-modified mosquitoes.”
BackgroundRecent Advances in the Application of CRISPR/Cas9 Gene Editing System in Poultry Species
Khwatenge, C. N., & Nahashon, S. N. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.627714 · Cited by 83
Rapid DNA unwinding accelerates genome editing by engineered CRISPR-Cas9
Eggers, A. R., Chen, K., Soczek, K. M., Tuck, O. T., Doherty, E. E., Xu, B., Trinidad, M. I., Thornton, B. W., Yoon, P. H., & Doudna, J. A. (2024) · Cell · doi:10.1016/j.cell.2024.04.031 · Cited by 81
Mulder, C. L., Zheng, Y., Jan, S. Z., Struijk, R. B., Repping, S., Hamer, G., & van Pelt, A. M. M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw017 · Cited by 87
CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice
Huai, C., Jia, C., Sun, R., Xu, P., Min, T., Wang, Q., Zheng, C., Chen, H., & Lu, D. (2017) · Human Genetics · doi:10.1007/s00439-017-1801-z · Cited by 83
Biological and social challenges of human reproduction in a long-term Mars base
Szocik, K., Marques, R. E., Abood, S., Kędzior, A., Lysenko-Ryba, K., & Minich, D. (2018) · Futures · doi:10.1016/j.futures.2018.04.006 · Cited by 79
“The method of CRISPR makes possible adaptive genetic engineering (Ran F. A. et al. 2013; Kleinstiver et al. 2016).”
MethodApplications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
Lim, K. R. Q., Yoon, C., & Yokota, T. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8040038 · Cited by 80
Cancellieri, S., Canver, M. C., Bombieri, N., Giugno, R., & Pinello, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz867 · Cited by 76
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.014 · Cited by 70
Recent application of CRISPR-Cas12 and OMEGA system for genome editing
Badon, I. W., Oh, Y., Kim, H., & Lee, S. H. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.013 · Cited by 78
Distinct patterns of Cas9 mismatch tolerance in vitro and in vivo
Fu, B. X. H., St. Onge, R. P., Fire, A. Z., & Smith, J. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw417 · Cited by 72
Scheben, A., & Edwards, D. (2017) · Science · doi:10.1126/science.aal4680 · Cited by 76
Vlčko, T., & Ohnoutková, L. (2020) · Plants · doi:10.3390/plants9020195 · Cited by 74
“Additionally, efforts have been made to increase the specificity and efficacy of Cas9 by altering its amino acid sequence [44,45] or sgRNA sequence [46].”
BackgroundGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
CRISPR/Cas9 gene-editing strategies in cardiovascular cells
Vermersch, E., Jouve, C., & Hulot, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz250 · Cited by 79
Bisaria, N., Jarmoskaite, I., & Herschlag, D. (2017) · Cell Systems · doi:10.1016/j.cels.2016.12.010 · Cited by 76
Ando, H., Hirose, M., & Mikoshiba, K. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811129115 · Cited by 77
“We disrupted all three IP3R subtypes, IP3R1, IP3R2, and IP3R3, by CRISPR/Cas9 genome editing using a highfidelity Cas9 nuclease (35).”
MethodHighly efficient and genotype-independent barley gene editing based on anther culture
Han, Y., Broughton, S., Liu, L., Zhang, X.-Q., Zeng, J., He, X., & Li, C. (2021) · Plant Communications · doi:10.1016/j.xplc.2020.100082 · Cited by 73
“As a result, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) proteins have been discovered and used for precise genetic engineering (Jinek et al., 2012; Jiang et al., 2013; Hsu et al., 2014; Kleinstiver et al., 2016; Chen et al., 2019).”
BackgroundGuidelines for Optimized Gene Knockout Using CRISPR/Cas9
Campenhout, C. V., Cabochette, P., Veillard, A.-C., Laczik, M., Zelisko-Schmidt, A., Sabatel, C., Dhainaut, M., Vanhollebeke, B., Gueydan, C., & Kruys, V. (2019) · BioTechniques · doi:10.2144/btn-2018-0187 · Cited by 81
Gold Nanomaterials‐Implemented CRISPR‐Cas Systems for Biosensing
Fu, R., & Xianyu, Y. (2023) · Small · doi:10.1002/smll.202300057 · Cited by 76
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
“…one active center (Mali et al., 2013a; Ran et al., 2013), pairs of catalytically inactive Cas9 nucleases fused to the non-specific FokI nuclease (Guilinger et al., 2014; Tsai et al., 2014) or rationally engineered high precision Cas9 nucleases (Kleinstiver et al., 2016; Slaymaker et al., 2016).”
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 78
The applications of CRISPR /Cas system in molecular detection
Zhou, L., Peng, R., Zhang, R., & Li, J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13925 · Cited by 76
Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment
Kang, S.-H., Lee, W.-J., An, J.-H., Lee, J., Kim, Y.-H., Kim, H., Oh, Y., Park, Y., Jin, Y. B., Jun, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17418-8 · Cited by 77
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy
Robinson-Hamm, J. N., & Gersbach, C. A. (2016) · Human Genetics · doi:10.1007/s00439-016-1725-z · Cited by 83
Sakuma, T., Masaki, K., Abe‐Chayama, H., Mochida, K., Yamamoto, T., & Chayama, K. (2016) · Genes to Cells · doi:10.1111/gtc.12437 · Cited by 77
“Furthermore, highly specific variants of Cas9 nuclease protein containing amino acid mutations have also been reported recently (Kleinstiver et al. 2016; Slaymaker et al. 2016).”
BackgroundGenome Editing in Mice Using CRISPR/Cas9 Technology
Hall, B., Cho, A., Limaye, A., Cho, K., Khillan, J. S., & Kulkarni, A. B. (2018) · Current Protocols in Cell Biology · doi:10.1002/cpcb.57 · Cited by 84
Strategies for genetic manipulation of adult stem cell-derived organoids
Menche, C., & Farin, H. F. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00609-8 · Cited by 69
Li, Z., Wang, J., Xu, J.-P., Wang, J., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 93
“Over the years, continuous efforts have been made to construct high-fidelity Cas9 variants including eSpCas9(1.1) [49], SpCas9-HF1 [50], HypaCas9 [51], evoCas9 [52], HiFi Cas9 [53] and Sniper-Cas9 [54].”
InfluentialAlves, C. R. R., Ha, L. L., Yaworski, R., Sutton, E. R., Lazzarotto, C. R., Christie, K. A., Reilly, A., Beauvais, A., Doll, R. M., de la Cruz, D., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01132-z · Cited by 76
“20 versions of WT SpCas9, SpG, SpCas9-NRRH, SpCas9-NRTH and SpCas9-NRCH, as well as ABE8e versions of SpCas9 and SpRY bearing HF1 mutations (N497A/R661A/ Q695A/Q926A) or the HiFi mutation (R691A) 37, 44 ,46,47 .”
InfluentialSelf-citationGolden Gate Assembly of CRISPR gRNA expression array for simultaneously targeting multiple genes
Vad‐Nielsen, J., Lin, L., Bolund, L., Nielsen, A. L., & Luo, Y. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2271-5 · Cited by 79
Chang, W., Liu, W., Liu, Y., Zhan, F., Chen, H., Lei, H., & Liu, Y. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3348-2 · Cited by 72
Safe CRISPR: Challenges and Possible Solutions
Pineda, M., Lear, A., Collins, J. P., & Kiani, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.010 · Cited by 69
Rui, Y., Varanasi, M., Mendes, S., Yamagata, H. M., Wilson, D. R., & Green, J. J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.005 · Cited by 73
Reyes, Á. P., & Lanner, F. (2017) · Development · doi:10.1242/dev.139683 · Cited by 82
Enhancer SINEs Link Pol III to Pol II Transcription in Neurons
Policarpi, C., Crepaldi, L., Brookes, E., Nitarska, J., French, S. M., Coatti, A., & Riccio, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.019 · Cited by 75
New considerations for hiPSC-based models of neuropsychiatric disorders
Hoffman, G. E., Schrode, N., Flaherty, E., & Brennand, K. J. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0029-1 · Cited by 66
The prokaryotic Argonaute proteins enhance homology sequence-directed recombination in bacteria
Fu, L., Xie, C.-Y., Jin, Z., Tu, Z., Han, L., Jin, M., Xiang, Y., & Zhang, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz040 · Cited by 76
“Although a few improved CRISPR/Cas9 systems have been developed to prevent the off-target effects (51,52), their application in bacteria has not been evaluated to date.”
BackgroundGene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection
Allen, A. G., Chung, C.-H., Atkins, A., Dampier, W., Khalili, K., Nonnemacher, M. R., & Wigdahl, B. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02940 · Cited by 83
“A series of SpCas9 mutants have been identified that facilitate reduced off-target effects on undesired loci including a D1135E variant, eSpCas9 and SpCas9-HF1 (Kleinstiver et al., 2015, 2016; Slaymaker et al., 2016).”
BackgroundBridge helix arginines play a critical role in Cas9 sensitivity to mismatches
Bratovič, M., Fonfara, I., Chylinski, K., Gálvez, E. J. C., Sullivan, T. J., Boerno, S. T., Timmermann, B., Boettcher, M., & Charpentier, E. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0490-4 · Cited by 75
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 73
Liposome technologies towards colorectal cancer therapeutics
Sang, R., Stratton, B., Engel, A. F., & Deng, W. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.055 · Cited by 73
CRISPR/Cas-Based Biosensor As a New Age Detection Method for Pathogenic Bacteria
Chakraborty, J., Chaudhary, A. A., Khan, S.-U.-D., Rudayni, H. A., Rahaman, S. M., & Sarkar, H. (2022) · ACS Omega · doi:10.1021/acsomega.2c04513 · Cited by 78
Sniper2L is a high-fidelity Cas9 variant with high activity
Kim, Y.-H., Kim, N., Okafor, I. C., Choi, S.-C., Min, S., Lee, J., Bae, S.-M., Choi, K., Choi, J., Harihar, V., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01279-5 · Cited by 75
Self-citationRecent advances in therapeutic gene-editing technologies
Liu, D., Cao, D., & Han, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.026 · Cited by 77
Fine-Tuning Next-Generation Genome Editing Tools
Kanchiswamy, C. N., Maffei, M. E., Malnoy, M., Velasco, R., & Kim, J. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.03.007 · Cited by 76
Moyo, B., Bloom, K. M., Scott, T. A., Ely, A., & Arbuthnot, P. B. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.003 · Cited by 75
USH2A Gene Editing Using the CRISPR System
Fuster-García, C., García-García, G., González-Romero, E., Jaijo, T., Sequedo, M. D., Ayuso, C., Vázquez-Manrique, R. P., Millán, J. M., & Aller, E. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.08.003 · Cited by 68
Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease
Rueda, F. O., Bista, M., Newton, M. D., Goeppert, A. U., Cuomo, M. E., Gordon, E., Kröner, F., Read, J. A., Wrigley, J. D., Rueda, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01732-9 · Cited by 74
Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research
Aquino‐Jarquín, G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2142 · Cited by 76
Zhao, M., Wang, J., Luo, M., Luo, H., Zhao, M., Han, L., Zhang, M., Yang, H., Xie, Y., Jiang, H., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9021-6 · Cited by 78
Aglawe, S. B., Barbadikar, K. M., Mangrauthia, S. K., & Madhav, M. S. (2018) · 3 Biotech · doi:10.1007/s13205-018-1355-3 · Cited by 76
Wang, T., Li, Y., Fu, Y., Xie, H., Song, S., Qiu, M., Wen, J., Chen, M., Chen, G., Tian, Y., et al. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01081 · Cited by 73
Donohoue, P. D., Pacesa, M., Lau, E., Vidal, B., Irby, M. J., Nyer, D. B., Rotstein, T., Banh, L., Toh, M. S., Gibson, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.035 · Cited by 69
A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells
Waddington, S. N., Privolizzi, R., Karda, R., & O’Neill, H. C. (2016) · Current Stem Cell Reports · doi:10.1007/s40778-016-0037-5 · Cited by 75
CRISPR/Cas9-mediated genome editing in nonhuman primates
Kang, Y., Chu, C., Wang, F., & Niu, Y. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039982 · Cited by 70
Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections
Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Nahand, J. S., Piroozmand, A., Jajarmi, V., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112743 · Cited by 77
“Three high gene-editing performance CRISPR/Cas systems with negligible off-target cleavage must be a much safer option for the clinical use of CRISPR/Cas9-supported antiviral approach [233,234].”
BackgroundWang, D., Jin, S., Lu, Q., & Chen, Y. (2023) · Journal of Fungi · doi:10.3390/jof9030362 · Cited by 76
“Additionally, numerous studies have indicated that off-target effects in CRISPR-mediated gene modifications were reduced by using engineered Cas9 variants, including the high-fidelity variant SpCas9HF1 [112], enhanced specificity (by eSpCas9) [113], and hyper accuracy (by HypaCas9 [114], Cas9-NG [115], and xCas9 [100,…”
BackgroundEvolution of CRISPR/Cas Systems for Precise Genome Editing
Hryhorowicz, M., Lipiński, D., & Zeyland, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814233 · Cited by 80
“Currently, numerous high-fidelity Cas9 variants have been engineered or developed, such as SpCas9-HF1 [16], HiFiCas9 [17], evoCas9 [18], eSpCas9 [19], HypaCas9 [20], Sniper-Cas9 [21], and xCas9 3.7 [22].”
InfluentialState of the art CRISPR-based strategies for cancer diagnostics and treatment
Carlo, E. D., & Sorrentino, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00701-x · Cited by 79
Organoid technologies meet genome engineering
Nie, J., & Hashino, E. (2017) · EMBO Reports · doi:10.15252/embr.201643732 · Cited by 72
Tools and targets: the dual role of plant viruses in CRISPR–Cas genome editing
Uranga, M., & Daròs, J. (2023) · The Plant Genome · doi:10.1002/tpg2.20220 · Cited by 68
“In this context, Cas9 variants including SpCas9-VQR, SpCas9-EQR, Cas9-NG, and xCas9 3.7 with PAM requirements of 5′-NGA-3′, 5′-NGAG-3′, 5′-NG-3′, and 5′-NG/GAA/GAT-3′, respectively, have shown efficacy in several plant species (Kleinstiver et al., 2016; Zhang et al., 2019).”
BackgroundInfluentialIzmiryan, A., Ganier, C., Bovolenta, M., Schmitt, A., Mavilio, F., & Hovnanian, A. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.008 · Cited by 68
A panel of eGFP reporters for single base editing by APOBEC-Cas9 editosome complexes
Martin, A. S., Salamango, D. J., Serebrenik, A. A., Shaban, N. M., Brown, W. L., & Harris, R. S. (2019) · Scientific Reports · doi:10.1038/s41598-018-36739-9 · Cited by 67
Perspectives in primary hyperoxaluria — historical, current and future clinical interventions
Shee, K., & Stoller, M. L. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00543-4 · Cited by 71
Yang, E., Metzloff, M., Langmüller, A. M., Xu, X., Clark, A. G., Messer, P. W., & Champer, J. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac081 · Cited by 71
Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering
Huang, X., Yang, D., Zhang, J., Xu, J., & Chen, Y. E. (2022) · Cells · doi:10.3390/cells11142186 · Cited by 69
Bompiani, K. M., Tsai, C., Achatz, F. P., Liebig, J. K., & Howell, S. B. (2016) · Metallomics · doi:10.1039/c6mt00076b · Cited by 68
Cooper, C. A., Challagulla, A., Jenkins, K. A., Wise, T. G., O’Neil, T. E., Morris, K. R., Tizard, M. L., & Doran, T. J. (2016) · Transgenic Research · doi:10.1007/s11248-016-0003-0 · Cited by 72
A history of genome editing in mammals
Fernández, A., Josa, S., & Montoliu, L. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9699-2 · Cited by 78
High-Throughput Approaches to Pinpoint Function within the Noncoding Genome
Montalbano, A., Canver, M. C., & Sanjana, N. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.017 · Cited by 68
“Another approach to reducing off-target activity is to use nucleases engineered with reduced off-target potential such as HypaCas9, SpCas9-HF1, and eSpCas9 (Chen et al., 2017b; Kleinstiver et al., 2016; Slaymaker et al., 2016).”
Structure and Dynamics of Cas9 HNH Domain Catalytic State
Zuo, Z., & Liu, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-17578-6 · Cited by 76
CRISPR-Cas9-based genome-wide screening of Toxoplasma gondii
Sidik, S. M., Huet, D., & Lourido, S. (2018) · Nature Protocols · doi:10.1038/nprot.2017.131 · Cited by 72
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 73
Farhang, N., Ginley-Hidinger, M., Berrett, K. C., Gertz, J., Lawrence, B. D., & Bowles, R. D. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.005 · Cited by 70
“This limitation will be considered in future work by using CRISPR systems that have been modified to reduce off-target effects.(39) Overall, all of these data indicate that when robust gene regulation is achieved, epigenome editing of inflammatory receptors can modulate inflammatory signaling in pathological IVD cells.”
BackgroundMethodBrain Organoids as Tools for Modeling Human Neurodevelopmental Disorders
Adams, J. W., Cugola, F. R., & Muotri, A. R. (2019) · Physiology · doi:10.1152/physiol.00005.2019 · Cited by 74
Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies
McTague, A., Rossignoli, G., Ferrini, A., Barral, S., & Kurian, M. A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.630600 · Cited by 67
Fam72a enforces error-prone DNA repair during antibody diversification
Rogier, M., Moritz, J., Robert, I., Lescale, C., Heyer, V., Abello, A., Martin, O. A., Capitani, K., Thomas, M., Thomas-Claudepierre, A.-S., et al. (2021) · Nature · doi:10.1038/s41586-021-04093-y · Cited by 69
CRISPR/Cas9-Based Genome Editing and Its Application in Aspergillus Species
Jin, F., Wang, B., Wang, Z., Jin, L., & Han, P. D. (2022) · Journal of Fungi · doi:10.3390/jof8050467 · Cited by 68
“This mutant is designed to significantly reduce the non-specific DNA contacts with mismatched sequences while retaining on-target activities, thus reducing the risk of off-target [70].”
BackgroundShabbir, R., Javed, T., Afzal, I., Sabagh, A. E., Ali, A., Vicente, Ó., & Chen, P. (2021) · Agronomy · doi:10.3390/agronomy11061042 · Cited by 73
“However, selecting specific promoters with truncated gRNA–Cas9 complexes can provide high mutation rates with minimum off-target effects [80].”
BackgroundLysosomal storage diseases: current therapies and future alternatives
Leal, A. F., Espejo-Mojica, A. J., Sánchez, O. F., Ramírez, C. M., Reyes, L. H., Cruz, J. C., & Alméciga-Díaz, C. J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01935-6 · Cited by 67
Genome editing in cardiovascular diseases
(2021) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.01.021 · Cited by 65
In-depth assessment of the PAM compatibility and editing activities of Cas9 variants
Zhang, W., Yin, J., Zhang-Ding, Z., Xin, C., Liu, M., Wang, Y., Ai, C., & Hu, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab507 · Cited by 65
“1) and HF1 weaken the binding affinity between Cas9/sgRNA and DNA sequences to improve target specificity (11,12), while HypaCas9 enhances the proofreading capacity to improve CRISPR– Cas9 targeting accuracy (13).”
BackgroundGene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“Taking the CRISPR system as an example, DNA recognition of the Cas-sgRNA complex cannot guarantee 100% specificity, as mismatches or other subtle changes in the target DNA can be tolerated (Hsu et al., 2013; Kleinstiver et al., 2016b; Strecker et al., 2019a; Tsai et al., 2015).”
BackgroundCRISPR-Cas gene editing technology and its application prospect in medicinal plants
Guo, M., Chen, H., Dong, S., Zhang, Z., & Luo, H. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00584-w · Cited by 70
“SpCas9-HF1 N497A, R661A, Q695A, Q926A of SpCas9 mutations NGG Enhanced specificity [64]”
BackgroundEngineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 70
Genome Editing in Sugarcane: Challenges Ahead
Mohan, C. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.01542 · Cited by 68
“Kleinstiver et al. (2016) reported novel modified Cas9 variants by substituting 3–4 amino acids, which could also be exploited to address the off-target problems in plants.”
BackgroundDelivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy
Wang, L., Zheng, W., Liu, S., Li, B., & Jiang, X. (2019) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 64
Nanovehicles for Plant Modifications towards Pest- and Disease-Resistance Traits
Kumar, S., Nehra, M., Dilbaghi, N., Marrazza, G., Tuteja, S. K., & Kim, K. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.10.007 · Cited by 66
Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing
Li, J., Hong, S., Chen, W., Zuo, E., & Yang, H. (2019) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.002 · Cited by 63
Maggio, I., Zittersteijn, H. A., Wang, Q., Liu, J., Janssen, J. M., Ojeda, I. T., van der Maarel, S. M., Lankester, A. C., Hoeben, R. C., & Gonçalves, M. A. F. V. (2020) · Gene Therapy · doi:10.1038/s41434-019-0119-y · Cited by 65
The CRISPR toolbox in medical mycology: State of the art and perspectives
Morio, F., Lombardi, L., & Butler, G. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008201 · Cited by 70
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.